Last Updated: May 10, 2026

Profile for Ecuador Patent: SP077989


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Ecuador Patent: SP077989

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Jun 16, 2026 Assertio Speclty CAMBIA diclofenac potassium
⤷  Start Trial Jun 16, 2026 Assertio Speclty CAMBIA diclofenac potassium
⤷  Start Trial Jun 16, 2026 Assertio Speclty CAMBIA diclofenac potassium
⤷  Start Trial Jun 16, 2026 Assertio Speclty CAMBIA diclofenac potassium
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Key insights for pharmaceutical patentability - Ecuador patent ECSP077989

Last updated: April 25, 2026

Ecuador ECSP077989: Scope, Claims, and Patent Landscape

What does Ecuador patent ECSP077989 cover?

ECSP077989 is an Ecuador-issued patent application/grant record tied to a drug-related technology (pharmaceutical). The document record name on file indicates “ECSP077989” as the identifier, with status and bibliographic fields listed in Ecuador’s IP register. However, the public record content needed to extract the exact therapeutic indication, active ingredient, formulation, claim set, and dependency structure is not present in the information provided here.

Because the analysis must be grounded in the actual claim text, claim numbering, and legal status content for ECSP077989, this cannot be completed accurately from the supplied material.

What are the exact claim boundaries for ECSP077989?

A claim-scope analysis requires, at minimum, the independent claim(s) and the full dependency chain (dependent claims, fallback language, Markush group boundaries, product-by-process vs product claims, dosing/regimen language, and any limitation to specific salts/polymorphs/solvates). Those elements are not included in the provided input.

As a result, a complete and accurate claim chart, scope summary, and “what is and is not covered” mapping cannot be produced for ECSP077989.

What is the drug patent landscape around ECSP077989 in Ecuador?

A landscape assessment for Ecuador requires, at minimum:

  • Public patent family links (priority application, continuations/divisionals, national phase entries)
  • Ecuador counterparts (EP/WO/US/CN/JPO family members that entered Ecuador)
  • Any relevant opposition/invalidity history and current legal status
  • Related use patents (methods of treatment, formulations) that might be drafted around the same scaffold
  • Potential patent term adjustments/extensions where applicable

None of this family linkage, legal status, or citation network is present in the provided material. Without it, landscape conclusions cannot be made without inventing facts.


Key Takeaways

  • ECSP077989 is referenced as a drug patent identifier, but the claim text, scope-defining claim language, and family/legal-status details required for an accurate scope and landscape analysis are not available in the provided input.
  • A correct breakdown of claim boundaries (independent and dependent claim scopes), design-around routes, and Ecuador-specific landscape mapping cannot be produced from the current information.
  • No reliable citation-backed conclusions on protected subject matter, coverage perimeter, or competing patents in Ecuador can be stated.

FAQs

1) Can you summarize the protected drug claims for ECSP077989?

Not from the information provided. A scope summary requires the actual independent and dependent claim language.

2) Does ECSP077989 cover a specific molecule, salt, polymorph, or formulation?

That cannot be determined without the claim text or bibliographic content showing the active ingredient and specific chemical/formulation limitations.

3) Is ECSP077989 part of a larger patent family with filings in other countries?

Family linkages are not included in the provided material, so no family mapping can be stated.

4) What competing patents might block or overlap with ECSP077989 in Ecuador?

Competing patents and overlap depend on family citations, claim scope, and Ecuador legal status records that are not present in the supplied input.

5) Can you provide a claim chart and freedom-to-operate view for Ecuador?

A claim chart and FTO view require the exact claim set and legal status, which are not available in the provided material.


References

No cited sources were included because the provided input does not contain any patent-register text, claim text, bibliographic fields, or extractable public document references for ECSP077989.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.